Danielle R Adams, Heidi Allen, Ginger E Nicol, Leopoldo J Cabassa
{"title":"Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science.","authors":"Danielle R Adams, Heidi Allen, Ginger E Nicol, Leopoldo J Cabassa","doi":"10.1093/tbm/ibae053","DOIUrl":null,"url":null,"abstract":"<p><p>Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use disorders. The U.S. Food and Drug Administration has acknowledged the promise of PAT, signaling potential approval of psilocybin-assisted therapy for depression by 2026. Given this timeline, implementation scientists must engage with PAT researchers, policymakers, and practitioners to think critically about bringing these promising new treatments into routine practice settings while maintaining quality and safety. This commentary aims to initiate a dialogue between implementation scientists and PAT researchers and practitioners on addressing these questions with a lens toward equity. Specifically, we discuss how the field of implementation science can support PAT stakeholders to accelerate the translational process from research into practice, focusing specifically on safety-net settings (i.e., Federally Qualified Health Centers and Veterans Affairs health systems) that serve historically marginalized populations. We use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework to illustrate five critical areas where implementation science can help move PAT from research into real-world practice. For each RE-AIM dimension, we highlight ways the field of implementation science can contribute tools (e.g., implementation strategies), methodologies (e.g., pragmatic hybrid implementation-effectiveness trials), and approaches (community-based participatory research) for establishing the safety, effectiveness, and accessibility of PAT for historically underserved communities.</p>","PeriodicalId":48679,"journal":{"name":"Translational Behavioral Medicine","volume":" ","pages":"744-752"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Behavioral Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/tbm/ibae053","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use disorders. The U.S. Food and Drug Administration has acknowledged the promise of PAT, signaling potential approval of psilocybin-assisted therapy for depression by 2026. Given this timeline, implementation scientists must engage with PAT researchers, policymakers, and practitioners to think critically about bringing these promising new treatments into routine practice settings while maintaining quality and safety. This commentary aims to initiate a dialogue between implementation scientists and PAT researchers and practitioners on addressing these questions with a lens toward equity. Specifically, we discuss how the field of implementation science can support PAT stakeholders to accelerate the translational process from research into practice, focusing specifically on safety-net settings (i.e., Federally Qualified Health Centers and Veterans Affairs health systems) that serve historically marginalized populations. We use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework to illustrate five critical areas where implementation science can help move PAT from research into real-world practice. For each RE-AIM dimension, we highlight ways the field of implementation science can contribute tools (e.g., implementation strategies), methodologies (e.g., pragmatic hybrid implementation-effectiveness trials), and approaches (community-based participatory research) for establishing the safety, effectiveness, and accessibility of PAT for historically underserved communities.
迷幻剂(如 3,4-亚甲二氧基甲基苯丙胺 [MDMA]、麦角酰二乙胺 [LSD]、迷幻药)是一种分子,与心理疗法搭配可产生快速治疗效果。迷幻药辅助心理疗法(PAT)的随机临床试验显示,对创伤后应激障碍(PTSD)、抑郁症和药物使用障碍的治疗效果很好。美国食品和药物管理局已经承认了 PAT 的前景,表示可能在 2026 年之前批准使用迷幻药辅助疗法治疗抑郁症。考虑到这一时间表,实施科学家必须与 PAT 研究人员、政策制定者和从业人员合作,批判性地思考如何在保证质量和安全的前提下将这些前景广阔的新疗法引入常规实践环境。本评论旨在启动实施科学家与 PAT 研究人员和从业人员之间的对话,以公平的视角解决这些问题。具体来说,我们讨论了实施科学领域如何支持 PAT 的利益相关者加快从研究到实践的转化过程,特别关注服务于历史上被边缘化人群的安全网环境(即联邦合格卫生中心和退伍军人事务卫生系统)。我们使用 "覆盖、效果、采用、实施和维护"(RE-AIM)框架来说明实施科学可以帮助将 PAT 从研究转化为现实世界实践的五个关键领域。对于 RE-AIM 的每一个维度,我们都强调了实施科学领域可以提供工具(如实施策略)、方法(如务实的混合实施效果试验)和途径(基于社区的参与式研究)的方式,以便为历史上服务不足的社区建立起 PAT 的安全性、有效性和可及性。
期刊介绍:
Translational Behavioral Medicine publishes content that engages, informs, and catalyzes dialogue about behavioral medicine among the research, practice, and policy communities. TBM began receiving an Impact Factor in 2015 and currently holds an Impact Factor of 2.989.
TBM is one of two journals published by the Society of Behavioral Medicine. The Society of Behavioral Medicine is a multidisciplinary organization of clinicians, educators, and scientists dedicated to promoting the study of the interactions of behavior with biology and the environment, and then applying that knowledge to improve the health and well-being of individuals, families, communities, and populations.